Plasminogen activator inhibitor type 2 in human corneal epithelium

Investigative Ophthalmology and Visual Science

Volumn 40, Issue 8, 1999, Pages 1669-1675

  Williams, Darice L ^c   Risse, Barbara ^c   Sam, Kim ^c   Saunders, Darren ^c   Orlin, Stephen ^c   Baker, Mark S ^a   Jensen, Pamela J ^c   Lavker, Robert M ^b  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 2;

ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CELL PROTECTION; CORNEA EPITHELIUM; EPITHELIUM CELL; HUMAN; HUMAN CELL; KERATINOCYTE; PRIORITY JOURNAL; SQUAMOUS EPITHELIUM;

BLOTTING, WESTERN; CELLS, CULTURED; EPITHELIUM, CORNEAL; HUMANS; IMMUNOENZYME TECHNIQUES; PLASMINOGEN ACTIVATOR INHIBITOR 2; SERINE PROTEINASE INHIBITORS;

EID: 0033031346     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Fini ME, Parks WC, Rinehart WB, et al. Role of matrix metalloproteinases in failure to re-epithelialize after corneal injury. Am J Pathol. 1996;149:1287-1302.
2. Whitelock RB, Fukuchi T, Zhou L, et al. Cathepsin G, acid phosphatase, and alpha 1-proteinase inhibitor messenger RNA levels in keratoconus corneas. Invest Ophthalmol Vis Sci. 1997;38:529-534.
3. Hayashi K, Sueishi K. Fibrinolytic activity and species of plasminogen activator in human tears. Exp Eye Res. 1988;46:131-137.
4. Hayashi K, Berman M, Smith D, el-Ghatit A, Pease S, Kenyon KR. Pathogenesis of corneal epithelial defects: role of plasminogen activator. Curr Eye Res. 1991;10:381-398.
5. Mirshahi M, Mirshahi S, Soria C, Thomaidis A, Pouliquen Y, Faure JP. Production of proteases type plasminogen activator and their inhibitor in cornea. Biochem Biophys Res Commun. 1989;160: 1021-1025.
6. Tripathi RC, Tripathi BJ, Park JK. Localization of urokinase-type plasminogen activator in human eyes: an immunocytochemical study. Exp Eye Res. 1990;51:545-552.
7. Vassalli J-D, Sappino A-P, Belin D. The plasminogen activator/ plasmin system. J Clin Invest. 1991;88:1067-1072.
8. Andreasen PA, Georg B, Lund LR, Ricco A, Stacey SN. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol. 1990;68:1-19.
9. Blasi F, Vassalli J-D, Dano K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol. 1987; 104:801-804.
10. Carmeliet P, Collen D. Gene targeting and gene transfer studies of the biological role of the plasminogen/plasmin system. Thromb Haemost. 1995;74:429-436.
11. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997;72:1-22.
12. Mignatti P, Rifkin DB. Plasminogen activators and angiogenesis. Curr Top Microbiol Immunol. 1996;213:33-50.
13. Tsirka SE, Rogove AD, Bugge TH, Degan JL, Strickland S. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J Neurosci. 1997;17:543-552.
14. Rømer J, Lund LR, Eriksen J, Pyke C, Kristensen P, Danø K. The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds. J Invest Dermatol. 1994;102:519-522.
15. Rømer J, Bugge TH, Pyke C, et al. Impaired wound healing in mice with a disrupted plasminogen gene. Nat Med. 1996;2:287-292.
16. Grøndahl-Hansen J, Lund LR, Ralfkiaer E, Ottevanger V, Danø K. Urokinase- and tissue-type plasminogen activators in keratinocytes during wound re-epithelialization in vivo. J Invest Dermatol. 1988; 90:790-795.
17. Kramer MD, Schaefer B, Reinartz J. Plasminogen activation by human keratinocytes: molecular pathways and cell-biological consequences. Biol Chem Hoppe Seyler. 1995;376:131-141.
18. Grimaldi G. DiFiore P, Locatelli EK, Falco J, Blasi F. Modulation of urokinase plasminogen activator gene expression during the transition from quiescent to proliferative state in normal mouse cells. EMBO J. 1986;5:855-861.
19. Jensen PJ, Lavker RM. Modulation of the plasminogen activator cascade during enhanced epidermal proliferation in vivo. Cell Growth Diff. 1996;7:1793-1804.
20. McNeill H, Jensen PJ. A high-affinity receptor for urokinase plasminogen activator on human keratinocytes: characterization and potential modulation during migration. Cell Reg. 1990;1:843-852.
21. Chen C-S, Lyons-Giordano B, Lazarus GS, Jensen PJ. Differential expression of plasminogen activators and their inhibitors in an organotypic skin co-culture system. J Cell Sci. 1993;106:45-53
22. Hibino H, Izaki S, Ohkuma S, Kon S, Thorsen S, Astedt B. Epidermal plasminogen activator inhibitor (PAI) is immunologically identical to placental-type PAI-2. FEBS Lett. 1988;231:202-206.
23. Lyons-Giordano B, Loskutoff D, Chen CS, Lazarus G, Keeton M, Jensen PJ. Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis. Histochemistry. 1994;101:105-112.
24. Lavker RM, Risse B, Brown H, et al. Localization of plasminogen activator inhibitor type 2 (PAI-2) in hair and nail: implications for terminal differentiation. J Invest Dermatol. 1998;110:917-922.
25. Risse BC, Brown H, Lavker RM, et al. Differentiating cells of murine stratified squamous epithelia constitutively express plasminogen activator inhibito type 2 (PAI-2). Histochem Cell Biol. 1998;110: 559-569
26. Remold-O'Donnell E. The ovalbumin family of serpin proteins. FEBS Lett. 1993;315:105-108.
27. Astedt B, Lecander I, Brodin T, Lundblad A, Low K. Purification of a specific placental plasminogen activator inhibitor by monoclonal antibody and its complex formation with plasminogen activator. Thromb Haemost. 1985;53:122-125.
28. Wun T-C, Reich E. An inhibitor of plasminogen activation from human placenta: purification and characterisation. J Biol Chem. 1987;262:3646-3653.
29. Wohlwend A, Belin D, Vassalli J-D. Plasminogen activator-specific inhibitors produced by human monocytes/macrophages. J Exp Med. 1987;165:320-339.
30. Kruithof EKO, Vassalli JD, Schleuning WD, Mattaliano RJ, Bachmann F. Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma line U-937. J Biol Chem. 1986;261:11207-11213.
31. Kruithof EKO, Baker MS, Bunn CL. Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 1995;86:4007-4024.
32. Schleef RR, Wagner NV, Loskutoff DJ. Detection of both type 1 and type 2 plasminogen activator inhibitors in human cells. J Cell Physiol. 1988;134:269-274.
33. Laug WE, Aebersold R, Jong A, Rideout W, Bergman BL, Baker J. Isolation of multiple types of plasminogen activator inhibitors from vascular smooth muscle cells. Thromb Haemost. 1989;61: 517-521.
34. Kumar S, Millis AJT, Baglioni C. Expression of interleukin 1-inducible genes and production of interleukin 1 by aging human fibroblasts. Proc Natl Acad Sci USA. 1992;89:4683-4687.
35. Kinnby B, Lecander I, Martinsson G, Astedt B. Tissue plasminogen activator and placental plasminogen activator inhibitor in human gingival fluid. Fibrinolysis. 1991;5:239-242.
36. Kinnby B, Borgstrom MK, Granath L, Lecander I, Sundin B. Tissue plasminogen activator (t-PA) and placental plasminogen activator inhibitor (PAI-2) in gingival fluid from 8-9 year-old children. Scand J Dent Res. 1993;101:279-281.
37. Jensen P, Wu Q, Janowitz P, Ando Y, Scheeter NM. Plasminogen activator inhibitor type 2: an intracellular keratinocyte differentiation product that is incorporated into the cornified envelope. Exp Cell Res. 1995;217:65-71.
38. Saunders DN, Buttigieg KML, Gould A, McPhun V, Baker MS. Immunological detection of conformational neoepitopes associated with the serpin activity of plasminogen activator inhibitor type-2. J Biol Chem. 1998;273:10965-10971.
39. Tsatas D, Baker MS, Rice GE. Tissue-specific expression of the relaxed conformation of plasminogen activator inhibitor-2 and low density lipoprotein receptor-related protein in human term gestational tissues. J Histochem Cytochem. 1997;45:1593-1602.
40. Wilczynska M, Fa M, Ohlsson P-I, Ny T. The inhibition mechanism of serpins. J Biol Chem. 1995;270:29652-29655.
41. Lindberg K, Brown ME, Chaves HV, Kenyon KR, Rheinwald JG. In vitro propagation of human ocular surface epithelial cells for transplantation. Invest Ophthalmol Vis Sci. 1993;34:2672-2679.
42. Wang Y, Jensen PJ. Regulation of the level and glycosylation state of plasminogen activator inhibitor type 2 during human keratinocyte differentiation. Differentiation. 1998;63:93-99.
43. Kiso U, Kaudewitz H, Henschen A, Astedt B, Kruithof EKO, Bachmann F. Determination of intermediates, products and cleavage site in the reaction between plasminogen activator inhibitor type-2 and urokinases. FEBS Lett. 1988;230:51-56.
44. Kumar S, Baglioni C. Protection from tumor necrosis-factor mediated cytolysis by overexpression of plasminogen activator inhibitor type 2. J Biol Chem. 1991;261:11207-11213.
45. Dickinson JL, Bates EJ, Ferrante A, Antalis TM. Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis: evidence for an alternative biological function. J Biol Chem. 1995;270:27894-27904.
46. Dickinson JL, Norris BJ, Jensen PH, Antalis TM. The CD interhelical domain of the serpin plasminogen activator inhibitor-type 2 is required for protection from TNF-α induced apoptosis. Cell Death Diff. 1998;5:163-171.
47. Boyle MDP, Lottenberg R. Plasminogen activation by invasive human pathogens. Thromb Haemost. 1997;77:1-10.
48. Howe TT, Iglewski BH. Isolation and characterization of alkaline protease-deficient mutants of Pseudomonas aeruginosa in vitro and in a mouse eye model. Infect Immunol. 1984;43:1058-1063.
49. Kawaharajo K, Homma JY. Pathogenesis of the mouse keratitis produced with Pseudomonas aeruginosa. Jpn J Exp Med. 1975; 45:515-524.
50. Ohman DE, Burns RP, Iglewski BH. Corneal infections in mice with toxin A and elastase mutants of Pseudomonas aeruginosa. J Infect Dis. 1980;142:547-555.
51. van Klink F, Alizadeh H, Stewart GL, et al. Characterization and pathogenic potential of a soil isolate and an ocular isolate of Acanthamoeba castellanii in relation to Acanthamoeba keratitis. Curr Eye Res. 1992;11:1207-1220.
52. Mitra MM, Alizadeh H, Gerard RD, Niederkorn JY. Characterization of a plasminogen activator produced by Acanthamoeba castellanii. Mol Biochem Pharmacol. 1995;73:157-164.
53. Antalis TM, Linn ML, Donnan K, et al. The serine proteinase inhibitor (serpin) plasminogen activator inhibitor type 2 protects against viral cytopathic effects by constitutive Interferon α/β priming. J Exp Med. 1998;187:1799-1811.